← Oncology Approval Tracker

FDA DECISION ·

Braftovi + Erbitux

encorafenib + cetuximab · Array BioPharma

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic colorectal cancer with a BRAF V600E mutation identified by an FDA-approved test after prior therapy.

LAMPGEN ANALYSIS

Why it matters

Established a BRAF-directed combination for a previously treated colorectal cancer population.

What research teams should watch

Record the precise BRAF variant and coordinate oral drug supply with infusion visits.

PRIMARY RECORDS

Sources